Miyamoto T, Horie T, Shimada T, Kuwamura M, Baba E
Department of Veterinary Medicine, College of Agriculture, Osaka Prefecture University, Sakai, Japan.
J Am Anim Hosp Assoc. 1999 Nov-Dec;35(6):475-81. doi: 10.5326/15473317-35-6-475.
A 10-year-old, female shih tzu was diagnosed as having myelodysplastic syndrome (MDS) based on the presence of a nonregenerative anemia, dysplastic changes in the three hematopoietic cell lines, a normal to hypercellular bone marrow, and less than 30% blast cells of all nucleated cells in the bone marrow. Low-dose aclarubicin, a differentiation-induction therapy for MDS and atypical leukemias in humans, was administered. Hematological improvement was observed, and the dog lived for 809 days after the first presentation.
一只10岁雌性西施犬因出现非再生性贫血、三种造血细胞系的发育异常变化、骨髓正常至高细胞性以及骨髓中所有有核细胞的原始细胞少于30%，被诊断为患有骨髓增生异常综合征（MDS）。给予低剂量阿克拉霉素，这是一种用于人类MDS和非典型白血病的诱导分化疗法。观察到血液学改善，这只狗在首次就诊后存活了809天。
